Status:
COMPLETED
Chemoradiotherapy of NSCLC Stage IIIB
Lead Sponsor:
Intergroupe Francophone de Cancerologie Thoracique
Collaborating Sponsors:
Bristol-Myers Squibb
Pierre Fabre Laboratories
Conditions:
NSCLC Stage IIIB
Concomitant Radiochemotherapy
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
To evaluate the best timing of the concomitant chemoradiotherapy among patients with NSCLC stage III not resectable treated by concomitant chemo-radiotherapy, either preceded by a induction chemothera...
Detailed Description
Chemotherapy: C = Cisplatine : 80 mg/m² P = Paclitaxel : 200 mg/m² N = Vinorelbine : 15 mg/m² Radiotherapy: 66 Gy with 33 fractions (2 Gy/fraction, 1 fraction/day, 6,5 weeks) High energy Photons X ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- NSCLC stage IIIA N2 or IIIB not resectable, except N3 sus-clavicular, nor reached pleural
- PS = 0 or 1
- Possibility of including all the targets in only one exposure field
- Slimming \< 10% of the weight of the body
- Functions hepatic, renal and hematologic normal
- VEMS \>40% and PaO2 \>60 mmHg
- written and signed informed consent
- Exclusion criteria :
- \- NSCLC stage IV or wet-IIIB
Exclusion
Key Trial Info
Start Date :
March 1 2002
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT00198432
Start Date
March 1 2002
End Date
December 1 2006
Last Update
March 10 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Saint-Etienne Pneumologie
Saint-Etienne, France, 42000